MedTrace Logo

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

NCT05466799 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-02-13

No results posted yet for this study

Summary

The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer

Conditions

Interventions

DRUG

FOLFIRINOX chemotherapy

Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer

DEVICE

OncoSil™

Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance

Sponsors & Collaborators

  • OncoSil Medical Limited

    lead INDUSTRY

Principal Investigators

  • Michele Milella, MD, PhD · University Hospital of Verona

  • Giuseppe Malleo, MD, PhD · University Hospital of Verona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-26
Primary Completion
2026-01-26
Completion
2027-07-31

Countries

  • Australia
  • Belgium
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05466799 on ClinicalTrials.gov